Clinical trial · Interventional
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
A Phase I Open-label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.
NCT00502164CI-TRIAL-00004315AZD2171IL/0003completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Prostate Adenocarcinoma | Prostate Adenocarcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AZD2171 | Drug | Cediranib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To establish the safety and tolerability of AZD2171 in subjects with advanced prostate adenocarcinoma
Secondary outcomes (1)
- measure
- Explore the PK profile of AZD2171 at steady-state administration to subjects
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men, 18yrs and older * Histological or cytological confirmation of prostate adenocarcinoma (symptomatic or asymptomatic) * Prior hormonal therapy, and/or no more than 1 prior chemotherapy regimen (including estramustine and/or corticosteroids) for treatment of prostate adenocarcinoma Exclusion Criteria: * Prior radiotherapy to bone metastases within 4 weeks prior to screening * any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy * Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable with steroid treatment for 1 week.
References
Publications (0)
Data not yet available
No reference posted for this study.